Marella Thorell - 27 May 2021 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Accounting Officer
Signature
/s/ Marella Thorell
Issuer symbol
CNTA
Transactions as of
27 May 2021
Net transactions value
$0
Form type
4
Filing time
01 Jun 2021, 20:47:46 UTC
Next filing
04 Jun 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNTA Share Option (right to buy) Award $0 +58,956 $0.000000 58,956 29 Jan 2021 Ordinary Shares 58,956 $4.11 Direct F1, F2, F3, F4, F5
transaction CNTA Share Option (right to buy) Award $0 +9,487 $0.000000 9,487 29 Jan 2021 Ordinary Shares 9,487 $4.87 Direct F1, F2, F4, F5, F6
transaction CNTA Share Option (right to buy) Award $0 +208,474 $0.000000 208,474 19 Feb 2021 Ordinary Shares 208,474 $5.84 Direct F1, F2, F4, F5, F7
transaction CNTA Share Option (right to buy) Award $0 +137,500 $0.000000 137,500 27 May 2021 Ordinary Shares 137,500 $20.00 Direct F4, F5, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.
F2 This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
F3 56.25% of the shares subject to such option are vested as of January 29, 2021. The remaining 43.75% of the shares subject to such option shall vest and become exercisable monthly beginning on February 1, 2021.
F4 Represents A Ordinary Shares that will be redesignated as Ordinary Shares immediately prior to the closing of the initial public offering.
F5 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F6 25% of the shares subject to such option are vested as of January 29, 2021. The remaining 75% of the shares subject to such option shall vest and become exercisable monthly beginning on February 1, 2021.
F7 25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
F8 25% of the shares subject to such option shall vest and become exercisable on February 1, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.